PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023

Description: PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023

Summary

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjuncive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

The new therapies entering the AMD market will be the main driver of growth in this market, with the wAMD drugs Fovista, squalamine, and abicipar pegol launching into the French market in 2017, 2018, and 2020, respectively. The publisher estimates that the combined drug sales for ME and AMD in Italy during 2013 reached $348m.

Scope

- Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Macular Edema and Macular Degeneration market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Related Reports
3 Disease Overview
3.1 Macular Degeneration Overview
3.1.1 Etiology and Pathophysiology
3.1.2 Classification
3.1.3 Symptoms and Diagnosis
3.2 Macular Edema Overview
3.2.1 Etiology and Pathophysiology
3.2.2 Classification
3.2.3 Symptoms and Diagnosis
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Macular Edema Diagnosis
4.1.2 Macular Degeneration Diagnosis
4.1.3 Treatment Guidelines and Leading Prescribed Drugs
4.1.4 Clinical Practice
4.2 France
4.3 Germany
4.4 Italy
4.5 Spain
4.6 UK
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major Brands
5.2.1 Lucentis (ranibizumab)
5.2.2 Eylea (aflibercept)
5.2.3 Avastin (bevacizumab)
5.2.4 Macugen (pegaptanib sodium)
5.2.5 Visudyne (verteporfin)
5.2.6 Corticosteroid Implants
6 Unmet Need and Opportunity
6.1 Overview
6.2 Treatment for Dry AMD
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Longer-Acting Anti-VEGF Drug Therapy
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Less Invasive Drug Formulations
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Awareness and Earlier Patient Diagnosis
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Home Monitoring of AMD Progression
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Abicipar pegol
7.2.2 Fovista
7.2.3 Squalamine
7.2.4 Lampalizumab
7.2.5 Emixustat
7.3 Promising Drugs in Early-Stage Development
7.3.1 Complement Inhibitors
7.4 Other Drugs in Development
7.5 Biosimilars
8 Market Outlook
8.1 Global
8.1.1 Drivers and Barriers - Global Issues
Table 22: Product Profile - Ozurdex
Table 23: Product Profile - Iluvien
Table 24: Corticosteroid IVT Implants SWOT Analysis, 2014
Table 25: Unmet Needs and Opportunities in ME and AMD
Table 26: Promising Drugs in Clinical Development for ME and AMD
Table 27: Comparison of Drugs in Development for ME and AMD, 2014
Table 28: Product Profile - Abicipar pegol
Table 29: SWOT Analysis - Abicipar pegol, 2014
Table 30: Product Profile - Fovista
Table 31: SWOT Analysis - Fovista, 2014
Table 32: Product Profile - Squalamine
Table 33: SWOT Analysis - Squalamine, 2014
Table 34: Product Profile - Lampalizumab
Table 35: SWOT Analysis - Lampalizumab, 2014
Table 36: Product Profile - Emixustat
Table 37: SWOT Analysis - Emixustat, 2014
Table 38: Early-Stage Drugs in Clinical Development for ME and AMD, 2014
Table 39: ME and AMD Markets - Drivers and Barriers, 2013-2023
Table 40: Sales Forecast ($m) for ME in France, 2013-2023
Table 41: Sales Forecast ($m) for AMD in France, 2013-2023
Table 42: Key Events Impacting Sales for ME and AMD in France, 2013-2023
Table 43: ME and AMD Markets - Drivers and Barriers in Germany, 2013-2023
Table 44: Sales Forecast ($m) for ME in Germany, 2013-2023
Table 45: Sales Forecast ($m) for AMD in Germany, 2013-2023
Table 46: Key Events Impacting Sales for ME and AMD in Germany, 2013-2023
Table 47: ME and AMD Markets - Drivers and Barriers in Italy, 2013-2023
Table 48: Sales Forecast ($m) for ME in Italy, 2013-2023
Table 49: Sales Forecast ($m) for AMD in Italy, 2013-2023
Table 50: Key Events Impacting Sales for ME and AMD in Italy, 2013-2023
Table 51: ME and AMD Markets - Drivers and Barriers in Spain, 2013-2023
Table 52: Sales Forecast ($m) for ME in Spain, 2013-2023
Table 53: Sales Forecast ($m) for AMD in Spain, 2013-2023
Table 54: Key Events Impacting Sales for ME and AMD in Spain, 2013-2023
Table 55: ME and AMD Markets - Drivers and Barriers in the UK, 2013-2023
Table 56: Sales Forecast ($m) for ME in the UK, 2013-2023
Table 57: Sales Forecast ($m) for AMD in the UK, 2013-2023
Table 58: Key Events Impacting Sales for ME and AMD in the UK, 2013-2023
Table 59: ME and AMD Markets - Drivers and Barriers in the UK, 2013-2023
Table 60: Key Launch Dates
Table 61: Key Patent Expiries
Table 62: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

1.2 List of Figures
Figure 1: Anatomy of the Eye and Macula
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
Figure 3: Color Fundus Photographs of Dry and Wet AMD
Figure 4: FAF Imaging of GA
Figure 5: Imaging of wAMD
Figure 6: CMT in DME
Figure 7: RVOs (BRVO and CRVO) on an FA
Figure 8: Increased CRT in ME-RVO
Figure 9: ME Clinical Treatment Flowchart
Figure 10: AMD Clinical Treatment Flowchart
Figure 11: Eylea's Clinical Development in DME and ME-BRVO
Figure 12: Iluvien's and Ozurdex's Clinical Development in wAMD, dAMD, and DME
Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023
Figure 14: Abicipar Pegol's Clinical Development in wAMD and DME
Figure 15: Clinical and Commercial Positioning of abicipar pegol
Figure 16: Fovista's Clinical Development in wAMD
Figure 17: Clinical and Commercial Positioning of Fovista
Figure 18: Squalamine's Clinical Development in wAMD and DME
Figure 19: Clinical and Commercial Positioning of squalamine
Figure 20: Lampalizumab's Development in wAMD
Figure 21: Clinical and Commercial Positioning of lampalizumab
Figure 22: Emixustat Clinical Development in dAMD
Figure 23: Clinical and Commercial Positioning of emixustat
Figure 24: Individual Drug Sales for ME in France, 2013-2023
Figure 25: Individual Drug Sales for AMD in France, 2013-2023
Figure 26: Individual Drug Sales for ME in Germany, 2013-2023
Figure 27: Individual Drug Sales for AMD in Germany, 2013-2023
Figure 28: Individual Drug Sales for ME in Italy, 2013-2023
Figure 29: Individual Drug Sales for AMD in Italy, 2013-2023
Figure 30: Individual Drug Sales for ME in Spain, 2013-2023
Figure 31: Individual Drug Sales for AMD in Spain, 2013-2023
Figure 32: Individual Drug Sales for ME in the UK, 2013-2023
Figure 33: Individual Drug Sales for AMD in the UK, 2013-2023

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3128294/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023
Web Address: http://www.researchandmarkets.com/reports/3128294/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th></th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 6995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 13990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 20985</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: __________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World